SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: Biotechwantabe who wrote (3125)10/28/2020 7:28:33 PM
From: Felix B  Respond to of 3557
 
Pretty solid but I think if the real test is data from hospitalized patients.....that would be huge if they can show it reduces mortality or length of stay?



To: Biotechwantabe who wrote (3125)10/28/2020 7:50:17 PM
From: Miljenko Zuanic1 Recommendation

Recommended By
xr1

  Read Replies (2) | Respond to of 3557
 
When will Mr. Market stop doubting REGN anti-viral (bacterial) Abs potential? EBOLA results were not EXCIDENT!



To: Biotechwantabe who wrote (3125)10/29/2020 2:49:56 AM
From: Miljenko Zuanic1 Recommendation

Recommended By
CuttingEdge Bio

  Read Replies (1) | Respond to of 3557
 
From Sanofi, 3Q-2020

"Dupixent® (collaboration with Regeneron) generated sales of €918 million in the third quarter (up 68.6%). In the U.S., Dupixent® sales of €725 million (up 67.7%) were ..."
E= 1.17$, --->US $848M, which is in line with my projection. (and 10% growth, QvQ)
Ex-US= $226M, 30% growth QvQ (picking up some speed)

Europe =97e
Japan =48e

sanofi.com